Obermatt
See Similar Stocks →

Immunocore

NSQ:IMCR · US45258D1054
BiotechnologySmall

360

40
Profit price93
Owner Earnings Yield1
Dividend Yield1
Price/Sales73
EV / Gross Profit57
Price/Book27
Return on Capital77
Cash Return on Capital79
Return on Equity79
EBIT Margin49
Gross Profitability55
Accruals41
Owner Earnings Margin75
Sales growth45
Profit Growth59
Long-Term EPS Growth77
Reinvestment40
Price momentum21
Debt load29
Refinancing14
Debt Payback1
Liquidity67
Analyst ratings41
Opinion Changes50
Price Target Upside88
Market mood49
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Immunocore clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUK
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2007
Employees575
Websiteimmunocore.com
ISINUS45258D1054
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyDermatologyInfectious DiseasesDiabetesOncologyBiotechnologyMedicalPharmaceutical

Description

Immunocore Holdings plc is a commercial stage biotechnology company. The company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune disea…

Analysis

Middle-of-the-road

Immunocore Holdings plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is fragile. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
76
2026

All-time high

76

Jun 2026

All-time low

41

Mar 2026

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
73
—
—
—
Price/Earnings
100
—
—
—
Price/Book
27
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
77
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immunocore with its peers
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mereo BioPharma Group
NAQ:MREO
51
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BB Biotech
SWX:BION
96
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →